Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P109 - Topic: AS07-Singular Entities/Subtypes/AS07a-ARCH, CCUS, ICUS: PREVALENCE, DYNAMICS AND CLINICAL SIGNIFICANCE OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IN NEWLY DIAGNOSED CANCER PATIENTS

Autor: González, A. Pérez, Peralta-Garzón, S., Palomo, L., Navarro, V., Yordi, A. Molero, Tazón-Vega, B., Calvete, O., Salamero, O., Saumell, S., Rivero, E., Zamora, E., Saoudi, N., Fariñas, L., Torres-Esquius, S., Novoa, S., Garrido, S., Sola, M., Campelo, M., Alfonso, A., Montoro, M.J., Valcárcel, D.

Publikováno v: In Leukemia Research May 2023 128 Supplement

P075 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW CYTOKINES AND CHEMOKINES CONCENTRATIONS IN MYELODISPLASTIC NEOPLASMS

Autor: Yordi, A. Molero, Medina, D., Navarro, V., Montoro, M.J., González, A. Pérez, Saumell, S., Gallur, L., Tazón-Vega, B., Solas, T. Jiménez, López-Cadenas, F., Ezponda, T., Alfonso, A., Salamero, O., Diez-Campelo, M., Prosper, F., Valcárcel, D.

Publikováno v: In Leukemia Research May 2023 128 Supplement

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics

Autor: Diaz-Santa, J, Rodriguez-Romanos, R, Coll, R, Osca, G, Pratcorona, M, Gonzalez-Bartulos, M, Garrido, A, Angona, A, Talarn, C, Tormo, M, Arnan, M, Vives, S, Salamero, O, Tuset, E, Lloveras, N, Diez, I, Zamora, L, Bargay, J, Sampol, A, Cruz, D, Vila, J, Sitges, M, Garcia, A, Vall-Llovera, F, Esteve, J, Sierra, J, Gallardo, D

Publikováno v: EUROPEAN JOURNAL OF HAEMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
European Journal of Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol

Acute myeloid leukemia (AML) is a complex disease, and its treatment needs to be adjusted to the risk, which is conferred by cytogenetics and molecular markers. Cytarabine is the main drug to treat AML, and it has been suggested that the genotype of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0de3f782e0855fd4238afc83a97dfd43
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12988